Switzerland
· Delayed Price · Currency is CHF Addex Therapeutics Statistics
Total Valuation
Addex Therapeutics has a market cap or net worth of CHF 5.88 million. The enterprise value is 2.12 million.
| Market Cap | 5.88M |
| Enterprise Value | 2.12M |
Important Dates
The last earnings date was Monday, November 11, 2024.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Addex Therapeutics has 98.30 million shares outstanding. The number of shares has increased by 50.83% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 98.30M |
| Shares Change (YoY) | +50.83% |
| Shares Change (QoQ) | +72.24% |
| Owned by Insiders (%) | 18.99% |
| Owned by Institutions (%) | 2.78% |
| Float | 34.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.23 |
| PB Ratio | 0.46 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.49 |
| EV / Sales | 2.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.27 |
Financial Position
The company has a current ratio of 4.97, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.97 |
| Quick Ratio | 4.67 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -513.82 |
Financial Efficiency
Return on equity (ROE) is -126.29% and return on invested capital (ROIC) is -73.55%.
| Return on Equity (ROE) | -126.29% |
| Return on Assets (ROA) | -61.71% |
| Return on Capital (ROIC) | -73.55% |
| Revenue Per Employee | 37,532 |
| Profits Per Employee | 187,721 |
| Employee Count | 23 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +26.70% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +26.70% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.08 |
| Relative Strength Index (RSI) | 35.90 |
| Average Volume (20 Days) | 711,117 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Addex Therapeutics had revenue of CHF 863,232 and earned 4.32 million in profits. Earnings per share was 0.05.
| Revenue | 863,232 |
| Gross Profit | -6.11M |
| Operating Income | -11.20M |
| Pretax Income | -11.86M |
| Net Income | 4.32M |
| EBITDA | -11.07M |
| EBIT | -11.20M |
| Earnings Per Share (EPS) | 0.05 |
Balance Sheet
The company has 3.79 million in cash and 32,182 in debt, giving a net cash position of 3.76 million or 0.04 per share.
| Cash & Cash Equivalents | 3.79M |
| Total Debt | 32,182 |
| Net Cash | 3.76M |
| Net Cash Per Share | 0.04 |
| Equity (Book Value) | 12.65M |
| Book Value Per Share | 0.13 |
| Working Capital | 3.75M |
Cash Flow
In the last 12 months, operating cash flow was -7.83 million and capital expenditures -1,883, giving a free cash flow of -7.83 million.
| Operating Cash Flow | -7.83M |
| Capital Expenditures | -1,883 |
| Free Cash Flow | -7.83M |
| FCF Per Share | -0.08 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,298.01% |
| Pretax Margin | -1,373.53% |
| Profit Margin | 500.17% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -906.88% |
Dividends & Yields
Addex Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -50.83% |
| Shareholder Yield | -50.83% |
| Earnings Yield | 80.31% |
| FCF Yield | -133.18% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Addex Therapeutics has an Altman Z-Score of -32.87. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -32.87 |
| Piotroski F-Score | n/a |